Recently, the FLAURA study showed an impressive progression free survival (PFS) benefit of osimertinib against gefitinib (18.9 VS.10.2 months) 18, resulting in approval of osimertinib as the first-line treatment for patients with EGFR-mutated advanced NSCLC regardless of T790M mutation status. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.